[New XXXX inhibitor empagliflozin: modern and safe treatment of  @entity6 ].

@entity1 @entity13897 @entity2700 @entity353 @entity6 @entity470 @entity31504 @entity281 @entity10200 @entity551
Empagliflozin is agent of new antidiabetic drugs that cause @entity10200 blocking the @entity13897 reuptake in the proxi-mal tubule. The loss of 50-100 g of @entity13897 / 24 hours in the urine results in a reduction of fasting @entity13897 , especially post-prandial @entity13897 , the energy expenditure of 200-400 kcal / day and blood pressure lowering. Treatment efficacy does not decrease over time, as it is not dependent on its own insulin production. The work evaluates the safety of modern treatment with empagliflozin which will soon appear in the portfolio of antidiabetic agents in the Czech Republic. The conducted studies with a special focus on empagliflozin treatment have shown high efficacy, safety and good tolerability of drug. It has been described a higher incidence of @entity281 with non-severe course, especially in @entity1 . The drug does not cause hypoglycaemia. In combination with sulfonylurea hypoglycaemia may occur. Empagliflozin does not cause clinically significant @entity2700 or @entity551 in @entity1 about 60 years of age, but some caution in empagliflozin treatment should be in elderly and fragile @entity1 . The big convenience of empagliflozin is its clinically non-significant interactions with other drugs and simple dosage of 1 tablet / day orally. In conclusion, empagliflozin is highly effective oral antidiabetic agent with a potential of wide application in all stages of type 2 @entity6 in monotherapy or combined with other medication. The treatment is associated with @entity353 and blood pressure lowering. The drug is effective and safe until @entity470 45 ml / s, in lower values the treatment should be discontinued. The occurrence of side effects is rare, except increased incidence of @entity281 especially in @entity1 and increased risk of hypoglycaemia when empagliflozin is combined with sulfonylurea.Key words: @entity6 treatment - empagliflozin - HbA1c - @entity31504 .
